Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.
Wellcome Trust Genome Campus, EBI, Hinxton, Cambridge, UK.
Cell Death Dis. 2014 Feb 6;5(2):e1051. doi: 10.1038/cddis.2014.9.
The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.
将现有药物用于新的治疗应用，通常称为药物重定位，是一种快速且具有成本效益的药物发现方法。肿瘤学中的药物重定位通常是由体外实验证据启动的，该证据表明药物具有抗癌细胞毒性。任何独立的验证，证明体外观察到的效果在临床环境中可能是有效的，并且药物可能会影响体内患者的生存，这是至关重要的。尽管最近在计算药物重定位方面进行了相当多的努力，但在建模现有/新药在癌症管理中的潜力时，没有一项研究考虑到患者生存信息。因此，我们开发了 DRUGSURV；这是第一个使用从临床癌症表达数据集得出的患者生存信息来估计药物潜在影响的计算工具。DRUGSURV 提供了药物可以在特定临床情况下影响生存结果的统计证据，从而证明进一步研究该药物的抗癌潜力并指导临床试验设计是合理的。DRUGSURV 涵盖了已批准的药物（约 1700 种）和实验药物（约 5000 种），可在 http://www.bioprofiling.de/drugsurv 免费获得。
